Summary
Medtronic plc's (MDT) 10-K filing for the fiscal year ended April 28, 2022, showcases a company rebounding from the COVID-19 pandemic, with net sales reaching $31.7 billion, a 5% increase year-over-year. This growth was driven by the recovery of global procedural volumes across its diverse portfolio, which spans Cardiovascular, Medical Surgical, Neuroscience, and Diabetes segments. While overall sales increased, the company navigated challenges including supply chain disruptions, particularly in the latter part of the fiscal year, and the ongoing impact of COVID-19. Medtronic demonstrated solid financial management with free cash flow of $6.0 billion and continued commitment to shareholder returns through share repurchases and dividends. The company's strategic focus remains on innovation and market leadership, with significant investment in research and development to drive new product introductions and expand indications. Medtronic's diversified business model, geographic reach, and commitment to its mission of alleviating pain, restoring health, and extending life position it for continued resilience and growth in the global healthcare technology market.
Financial Highlights
55 data points| Revenue | $31.69B |
| Cost of Revenue | $10.14B |
| Gross Profit | $21.54B |
| SG&A Expenses | $10.29B |
| Operating Income | $5.75B |
| Interest Expense | $553.00M |
| Net Income | $5.04B |
| EPS (Basic) | $3.75 |
| EPS (Diluted) | $3.73 |
| Shares Outstanding (Basic) | 1.34B |
| Shares Outstanding (Diluted) | 1.35B |
Key Highlights
- 1Net sales increased by 5% to $31.7 billion, driven by the recovery of global procedural volumes post-COVID-19.
- 2The Cardiovascular segment saw a 6% increase in net sales, driven by growth in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic divisions.
- 3The Medical Surgical segment experienced an 11% increase in Surgical Innovations, though overall segment sales grew by 5% due to declines in Respiratory, Gastrointestinal, & Renal.
- 4Neuroscience sales grew by 7%, with strong performance in Specialty Therapies, partially offset by market dynamics in China.
- 5The Diabetes segment saw a 3% decrease in net sales, primarily due to U.S. market performance, despite international growth in the MiniMed 780G system.
- 6Medtronic generated $6.0 billion in free cash flow, demonstrating strong operational cash generation.
- 7The company repurchased approximately $2.5 billion of its ordinary shares in fiscal year 2022 and had $3.0 billion remaining under its share repurchase authorization.